

Hi Dana,

I was hoping you could answer a potentially complicated question.

With regard to STN 125525. There are a number of outstanding CR letters under STN125145. Could you please tell me what, if any , of these CR letters will have any impact on the quadracel application.

Specifically, I am concerned with STN 125145 supplements 269, (b) (4), 293, and (b) (4).

Thanks,

juan

*Juan C. Lacayo, Ph.D.  
LCDR, United States Public Health Service  
Regulatory Reviewer/Project Manager  
CMC Review Branch 1  
Division of Vaccines and Related Product & Applications  
Office of Vaccines Research & Review  
Center for Biologics Evaluation & Research  
U.S. Food and Drug Administration  
WOC2 2329 HFM-481  
1401 Rockville Pike  
Rockville, MD 20852  
Tel: 301-796-2640*

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.